Treatment of lentigo maligna with tazarotene 0.1% gel

Ketty Peris, S Chimenti, Am Carrozzo, L Citarella, C De Felice

Research output: Contribution to journalArticle

12 Citations (Scopus)


We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna.
Original languageEnglish
Pages (from-to)101-103
Number of pages3
JournalJournal of the American Academy of Dermatology
Publication statusPublished - 2004


  • Aged
  • Aged, 80 and over
  • Dermatologic Agents
  • Female
  • Gels
  • Humans
  • Hutchinson's Melanotic Freckle
  • Male
  • Nicotinic Acids


Dive into the research topics of 'Treatment of lentigo maligna with tazarotene 0.1% gel'. Together they form a unique fingerprint.

Cite this